Robert Glanzman

REPAIR-MS and REPAIR-PD: tackling disease progression with gold nanocrystals 8:23
REPAIR-MS and REPAIR-PD: tackling disease progression with gold nanocrystals
Robert Glanzman • 13 Oct 2021
Phase II and III studies of CNM-Au8 in ALS 1:32
Phase II and III studies of CNM-Au8 in ALS
Robert Glanzman • 13 Oct 2021
VISIONARY-MS update: bioenergetic nanocatalysts under investigation as a novel DMT in RRMS 2:15
VISIONARY-MS update: bioenergetic nanocatalysts under investigation as a novel DMT in RRMS
Robert Glanzman • 13 Oct 2021
CNM-Au8 gold nanocatalysts to slow disease progression in ALS 3:11
CNM-Au8 gold nanocatalysts to slow disease progression in ALS
Robert Glanzman • 1 Mar 2021
The perpetual multi-center multi-regimen Healy-ALS Platform trial 0:46
The perpetual multi-center multi-regimen Healy-ALS Platform trial
Robert Glanzman • 1 Mar 2021
VISIONARY-MS: pure gold nanocrystals for neurorepair and neuroprotection in MS 4:51
VISIONARY-MS: pure gold nanocrystals for neurorepair and neuroprotection in MS
Robert Glanzman • 1 Mar 2021
Can gold-based nanotechnology meet the need for neuro-reparative therapies in MS? 1:43
Can gold-based nanotechnology meet the need for neuro-reparative therapies in MS?
Robert Glanzman • 1 Mar 2021
REPAIR-MS: 31P-MRS imaging to assess the effects of CNM-Au8 in MS 3:30
REPAIR-MS: 31P-MRS imaging to assess the effects of CNM-Au8 in MS
Robert Glanzman • 1 Mar 2021
The content of VJNeurology is intended for healthcare professionals